Notably, serum IL-4 levels significantly increased (p = 0.001), and IL-12 levels also rose significantly (p = 0.03) in the beta glucan group, suggesting its potential as an immunomodulatory adjunct in breast cancer treatment. This evidence concerns the gene IL4 and breast carcinoma.